FDA told CVS Health its unapproved Pink Eye Relief Drops are an illegal new drug made by a manufacturer with serious quality violations.
What happened
FDA reviewed the CVS website in July 2023 and found "CVS Health Pink Eye Relief Drops" offered for sale with claims to relieve redness, burning, watery discharge and grittiness. FDA said the homeopathic eye product has no approved drug application and is therefore an unapproved new drug. FDA also said the contract manufacturer that makes it had significant CGMP (current good manufacturing practice, the minimum quality rules for drug making) violations, which makes the product adulterated, and raised safety concerns about silver sulfate used as a preservative.
What FDA found
The eye drops are a new drug sold without an FDA-approved application.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)Shipping the unapproved product across state lines is a prohibited act.
Sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Website and label claims to relieve redness, burning and watery discharge show the product is intended as a drug.
Section 201(g)(1), 21 U.S.C. 321(g)(1)The product is not generally recognized as safe and effective for its claimed uses, so it counts as a new drug.
Section 201(p), 21 U.S.C. 321(p)The product is adulterated because its contract manufacturer did not follow CGMP.
Section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Using silver sulfate as an eye preservative may not be suitable and harmless; long-term silver use can cause irreversible bluish-gray skin and eye discoloration and eye deposits that reduce night vision.
21 C.F.R. 200.50(b)(1)
What FDA wants
FDA asks CVS to write to CDER's Office of Unapproved Drugs and Labeling Compliance within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If CVS believes there is no violation, it must send its reasoning and evidence.
Who should pay attention
- retailers and store brands selling their own label OTC eye products
- companies using contract manufacturers for ophthalmic drugs
- brands whose eye products contain silver-based preservatives
This is a summary. Read the original letter on fda.gov.